2017;47:56681.e9
Tufts CSDD's updated 2024 estimate of the direct cost of a Phase 2 or 3 clinical trial puts it at approximately $40,000 per day, with a single day of delay now worth roughly $500,000 to $800,000 in lost prescription drug or biologic sales, a dramatic increase from the outdated $4 to $5 million per-day-of-delay industry estimate that had circulated since 1993 ( [97] ) ( [98] ), which Tufts characterized as "a gross misestimation for more than 25 years." Every added day spent building a more representative recruitment pipeline therefore carries a real, quantifiable opportunity cost that sponsors must weigh against the scientific and regulatory value of representative data, a tension the still-unfinished Diversity Action Plan guidance leaves unresolved for 2026 planning purposes
Potential Cognitive and Hormonal Benefits Beyond sleep and recovery, there are broader wellness benefits that the research around DSIP is starting to touch
Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia After Amputation in Rats Treated with Heparin, Warfarin, L-NAME, and L-Arginine
Potential Cartilage Protection: Some preliminary data suggests peptides derived from growth hormone may also support cartilage health, although more research is necessary to confirm AOD-9604s specific benefits in this area
Some of the urine analytes were non-specifically elevated in both IC/BPS and OAB, but some were specific to the respective groups, indicating their common and distinct inflammation-related pathomechanisms, respectively